LifeTech Scientific Valuation
Is 1302 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1302 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 1302's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 1302's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1302?
Key metric: As 1302 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 1302's PE Ratio? | |
|---|---|
| PE Ratio | 24.6x |
| Earnings | CN¥248.64m |
| Market Cap | CN¥6.12b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4x |
| Enterprise Value/EBITDA | 15.6x |
| PEG Ratio | 0.8x |
Price to Earnings Ratio vs Peers
How does 1302's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 23.4x | ||
1789 AK Medical Holdings | 28.8x | 29.1% | HK$5.8b |
2291 LEPU ScienTech Medical Technology (Shanghai) | 25.2x | n/a | HK$5.9b |
2172 MicroPort NeuroScientific | 21.7x | 22.5% | HK$5.2b |
1858 Beijing Chunlizhengda Medical Instruments | 18.1x | 29.6% | HK$5.0b |
1302 LifeTech Scientific | 24.6x | 29.5% | HK$6.6b |
Price-To-Earnings vs Peers: 1302 is expensive based on its Price-To-Earnings Ratio (24.6x) compared to the peer average (23.4x).
Price to Earnings Ratio vs Industry
How does 1302's PE Ratio compare vs other companies in the HK Medical Equipment Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
2393 Yestar Healthcare Holdings | 0.1x | n/a | US$20.68m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 1302 is expensive based on its Price-To-Earnings Ratio (24.6x) compared to the Hong Kong Medical Equipment industry average (15.1x).
Price to Earnings Ratio vs Fair Ratio
What is 1302's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 24.6x |
| Fair PE Ratio | 18.2x |
Price-To-Earnings vs Fair Ratio: 1302 is expensive based on its Price-To-Earnings Ratio (24.6x) compared to the estimated Fair Price-To-Earnings Ratio (18.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
OrbusNeich Medical Group Holdings
HK$3.4b
An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.
6929
HK$4.09
7D
-4.4%
1Y
-48.9%
Sinopharm Group
HK$64.3b
Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.
1099
HK$20.60
7D
-0.2%
1Y
6.1%
Hygeia Healthcare Holdings
HK$10.0b
Offers oncology healthcare services in the People's Republic of China.
6078
HK$16.12
7D
-5.8%
1Y
-67.0%